Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan could reveal brain tumor aggression without surgery

NCT ID NCT00850278

First seen Apr 21, 2026 · Last updated Jun 23, 2026 · Updated 6 times

Summary

This study tested a special PET scan tracer called FLT in 50 adults with brain tumors (gliomas or metastases). The goal was to see if FLT-PET can measure how fast tumor cells are growing, which could help doctors diagnose and predict tumor behavior better than current scans like MRI or MET-PET. Participants received FLT-PET, MET-PET, and MRI before surgery, and results were compared with lab tests and survival data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Caen University Hospital

    Caen, 14033, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FLT (a radioactive tracer for PET imaging)

What this could lead to

If successful, FLT-PET could become a better way to see how aggressive a brain tumor is without surgery, helping doctors plan treatment more accurately.

What could go wrong

This is a small, early imaging study (50 people) that only looks at whether the scan works, not whether it improves outcomes. The tracer may not be better than existing methods.

Conditions

The condition(s) this trial relates to.

brain cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.